CVS Health (CVS) Tops Q4 EPS by 4c; Confirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
CVS Health (CVS) PT Raised to $89 at UBS
February 10, 2017 8:51 AM ESTUBS analyst Michael Cherny reiterates Buy rating and raises price target on CVS Health Corp. (NYSE: CVS) to $89 (from $88.50), suggesting the companys continued PBM net new business is offset by ongoing weakness in retail.
Cherny comments, "CVS 4Q had a number of... More
CVS Health (CVS) PT Lowered to $84 at Evercore ISI; Keeps 'Buy'
February 9, 2017 12:11 PM ESTEvercore ISI lowered its price target on CVS Health (NYSE: CVS) to $84.00 (from $91.50) while maintaining a Buy rating. The analyst said management did an admirable job on the DIR fee issue and a reasonable job on gross to net / rebates.
Analyst Ross Muken commented, "While the quarter proved generally uneventful and guidance was reiterated on the surface (albeit some moving parts below dollar profit... More
